Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Global Allocation
  • Asset Class: Mixed Allocation
  • Geographic Focus: International

DWS Invest II - Global Bioinnovation

+ Add to Watchlist

DW2GBLC:LX

173.00 EUR 0.49 0.28%

As of 01:59:30 ET on 03/31/2015.

Snapshot for DWS Invest II - Global Bioinnovation (DW2GBLC)

Year To Date: +20.92% 3-Month: +20.92% 3-Year: - 52-Week Range: 105.36 - 179.84
1-Month: +4.49% 1-Year: +54.13% 5-Year: - Beta vs MXWO: -

Mutual Fund Chart for DW2GBLC

No chart data available.
  • DW2GBLC:LX 173.00
  • 1M
  • 1Y
Interactive DW2GBLC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DW2GBLC

DWS Invest II - Global Bioinnovation is an open-end fund incorporated in Luxembourg. The Fund's objective is to seek capital appreciation. The Fund will invest at least 70% of its assets in shares, stock certificates, convertible bonds, convertible debentures and warrant-linked bonds whose underlying warrants are for securities, participation and dividend-right certificates.

Inception Date: 07-15-2013 Telephone: 352-42101-1 Tel
Managers: MARTIN BERBERICH / NOUSHIN IRANI TURNER
Web Site: www.dws.lu

Fundamentals for DW2GBLC

NAV (on 2015-03-31) 173.00
Assets (M) (on 2015-03-31) 5.00
Fund Leveraged N
Minimum Investment 0.00
Minimum Subsequent Investment 1,000.00

Dividends for DW2GBLC

No dividends reported

Fees & Expenses for DW2GBLC

Front Load 5.00
Back Load 0.00
Current Mgmt Fee 1.50
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for DW2GBLC

Filing Date: 12/30/2014
Name Position Value % of Total
Celgene Corp 2,850 264,818 6.893%
Gilead Sciences Inc 3,300 261,739 6.813%
iShares Nasdaq Biotechnology E 1,000 251,056 6.535%
Biogen Inc 870 243,904 6.349%
BioMarin Pharmaceutical Inc 3,000 221,950 5.777%
CF Industries Holdings Inc 660 148,867 3.875%
Regeneron Pharmaceuticals Inc 440 147,131 3.830%
Alexion Pharmaceuticals Inc 866 132,031 3.437%
Eurofins Scientific SE 550 116,160 3.024%
Pall Corp 1,214 101,564 2.644%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil